Personalized Medicine
TriMark Publications, August 2007, Pages: 87
Personalized medicine and pharmacogenomics are inextricably linked. Pharmacogenomics is the use of genetic variations (such as SNPs, gene expression variability, or other molecular signatures) to understand and correlate with differential response to pharmaceutical agents (drugs). Pharmacogenomics can be deployed clinically to stratify patients into responders and non-responders and this practice is termed personalized medicine.
The purpose of this report is to describe the specific market segment of the diagnostics market called personalized medicine. To frame the context of current approaches, pharmacogenomics seeks to identify and validate the signature(s) of molecular analytes and these are converted to assays using the tools of molecular diagnostics. The deployment of these molecular diagnostics assays on defining and targeting patient populations is the domain of personalized medicine.
This study includes all of the generally-accepted imaging activities that are currently used in personalized medicine, including pharmacogenomics, genomics and theranostics. It examines associated clinical market segments in which personalized medicine has taken a prominent role including cancer treatment, cardiology and neurology markets.
1. Overview
1.1 Statement of Report
1.2 Scope of this Report
1.3 Methodology
1.4 Executive Summary
2. The Case for Pharmacogenomics and Personalized Medicine: Biology, Approaches, Pipeline and Regulatory Trends
2.1 Scope of this Section
2.2 Introduction to Pharmacogenomics/Personalized Medicine
2.3 The Compelling Case for Personalized Medicine
2.4 The Process of Drug Metabolism and Implications for Pharmacogenomics/Personalized Medicine
2.5 Examples of Personalized Medicine
2.5.1 Herceptin
2.5.2 Ziagen
2.5.3 Iressa
2.5.4 Erbitux
2.6 Personalized Medicine Product Pipeline
2.7 The Personalized Medicine Coalition
2.8 Regulatory Trends and Guidelines in the Personalized Medicine Space
2.9 FDA Approved Agendia’s MammaPrint® Diagnostic—The First IVDMIA to be Approved
2.10 A Changing Regulatory Landscape for Personalized Medicine
2.11 Patenting Personalized Medicine
2.11.1 U.S. Supreme Court Dismisses LabCorp Appeal
2.12 The Leading Edge of Personalized Medicine: Specific Examples of Clinical Situations Where Personalized Medicine is Appropriate and Being Used
2.12.1 EGFR Assay
2.12.2 Individualized Warfarin Therapy
2.12.3 UGT1A1 Molecular Assay for Camptosar
2.12.4 Response to Gleevec in Gastrointestinal Stromal Tumors
2.12.5 LabCorp, ARCA Personalized Medicine Deal for Cardiovascular Diseases
2.12.6 Osmetech Licenses Epidauros Biotechnologie AG CYP2D6 Biomarker to Push into Pharmacogenomics
3. Pharmacogenomics/Personalized Medicine: Qualitative and Quantitative Market Analysis
3.1 Scope of this Section
3.2 Market Analysis of Molecular Diagnostics as it Relates to Pharmacogenomics/Personalized Medicine
3.3 Snapshot of Diagnostics Industry Structure
3.4 The Case for Theranostics (Therapeutic/Companion Diagnostic)
3.5 Classification of Diagnostics by Risk
3.6 Personalized Medicine Market Analysis—Market Survey Data Characterizing the Qualitative and Quantitative Industry Parameters
3.7 Segmentation of the Personalized Medicine Marketplace
3.8 Timeline for Impact of Various Segments in Personalized Medicine
3.9 Challenges for Personalized Therapeutics Development
3.10 Molecular Diagnostics Technology Platforms and Their Impact on Personalized Medicine
3.11 Macro Trends in Personalized Medicine
3.12 Personalized Medicine: Industry SWOT Analysis
4. Company Profiles
4.1 Abbott Molecular, Inc./Vysis
4.2 Affymetrix, Inc.
4.3 Agendia
4.4 Celera Diagnostics
4.5 Cepheid
4.6 Clinical Data, Inc.
4.7 Dakocytomation
4.8 deCODE Genetics
4.9 DNA Direct, Inc.
4.10 DxS Ltd.
4.11 Exact Sciences Corp.
4.12 Exagen Diagnostics, Inc.
4.13 Gen-Probe
4.14 Genelex Corp.
4.15 Gene Logic, Inc.
4.16 Genentech, Inc.
4.17 Genomic Health, Inc.
4.18 Genzyme Genetics
4.19 Illumina
4.20 Luminex Corporation/Tm Biosciences
4.21 Monogram Biosciences
4.22 Myriad Genetics, Inc.
4.23 Nanogen
4.24 Osmetech plc
4.25 Perlegen Sciences, Inc.
4.26 PGxl Laboratories
4.27 Prometheus Laboratories, Inc.
4.28 Roche Diagnostics
4.29 Siemens Medical Solutions Diagnostics
4.30 Target Discovery, Inc.
4.31 Third Wave Technologies
4.32 Ventana Medical Systems
4.33 XDx, Inc.
Appendix 1: Qualitative Market Responses
LIST OF FIGURES
Figure 2.1: Phase I and II Processes of Drug Metabolism
Figure 2.2: Human Phase I Enzymes
Figure 2.3: Human Phase II Enzymes
Figure 2.4: Hepatic Distribution of Human CYP450
Figure 2.5: Relative Contribution of CYP450 Enzymes to Drug Metabolism 1
Figure 2.6: Genetic Components Determine Drug Metabolism
Figure 3.1: From Genetic Content to Personalized Medicine
Figure 3.2: The Lopsided Remuneration for Diagnostics
Figure 3.3: Breakout of the Molecular Diagnostics Marketplace
Figure 3.4: Molecular Diagnostics Market Segmentation
Figure 3.5: Molecular Diagnostics Market Segmentation by Technology
Figure 3.6: Market Survey Respondent Demographics
Figure 3.7: Breakout of the Respondent Pool by Affiliation
Figure 3.8: Segmentation of the Personalized Medicine Market
Figure 3.9: Personalized Medicine Market Drivers
Figure 3.10: Challenges in the Personalized Medicine Space
LIST OF TABLES
Table 2.1: Personalized Medicine at the Nexus Point
Table 2.2: Percentage of Non-Responders in Various Drug Classes
Table 2.3: High Profile Drug Withdrawals from the Marketplace
Table 2.4: Drug Metabolism Drives Drug Efficacy/Toxicity
Table 2.5: Population Frequency of the Various Cytochromes
Table 2.6: List of Personalized Medicine Tests
Table 2.7: Personalized Medicine Product Pipeline
Table 2.8: Marketed Personalized Therapies, 2006
Table 2.9: Current Targets, Drugs and Disease Areas Classified by their Clinical Applications
Table 3.1: Areas in Personalized Medicine—Timeline of Impact
Table 3.2: Impact of Personalized Medicine on Various Therapeutic Areas
Table 3.3: Hurdles in Personalized Medicine Development in Various Therapeutic Areas
Table 3.4: Various Molecular Diagnostics Technologies: Timeline for Impact
Table 3.5: Various Molecular Diagnostics Technologies: Impact on Different Therapeutic Areas in Personalized Medicine
Table 3.6: Various Molecular Diagnostics Technologies: Technical Challenges in the Deployment for Personalized Medicine
Table 3.7: Market Opportunities in Personalized Medicine
Table 3.8: Challenges for Market Adoption of the Various Personalized Medicine Tests
Table 3.9: Personalized Medicine Industry SWOT
- Abbott Molecular, Inc./Vysis
- Affymetrix, Inc.
- Agendia
- Celera Diagnostics
- Cepheid
- Clinical Data, Inc.
- Dakocytomation
- deCODE Genetics
- DNA Direct, Inc.
- DxS Ltd.
- Exact Sciences Corp.
- Exagen Diagnostics, Inc.
- Gen-Probe
- Genelex Corp.
- Gene Logic, Inc.
- Genentech, Inc.
- Genomic Health, Inc.
- Genzyme Genetics
- Illumina
- Luminex Corporation/Tm Biosciences
- Monogram Biosciences
- Myriad Genetics, Inc.
- Nanogen
- Osmetech plc
- Perlegen Sciences, Inc.
- PGxl Laboratories
- Prometheus Laboratories, Inc.
- Roche Diagnostics
- Siemens Medical Solutions Diagnostics
- Target Discovery, Inc.
- Third Wave Technologies
- Ventana Medical Systems
- XDx, Inc.
Product Samples
A sample for this product is available. Please Login/Register to download this sample.
Also available
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW6
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
